ArticleCancer reports (Hoboken, N.J.)2026
Salvage Therapy With Inotuzumab Ozogamicin in Relapsed/Refractory B-ALL After CAR-T Therapy and HSCT: A Case Series.
Article in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAlthough inotuzumab ozogamicin (InO) has been approved as an effective agent for patients with refractory/relapsed (r/r) B-cell acute lymphoblastic leukemia (B-ALL), data in the context of post chimeric antigen receptor (CAR)-T cell therapy and allogeneic hematopoietic stem cell transplantation (allo-HSCT) relapse are lacking. CASE: We report on a series of three heavily pretreated r/r B-ALL patients who relapsed after CAR-T therapy and allo-HSCT and were salvage treated with InO. All achieved bone marrow (BM) remission with negative minimal residual disease (MRD) after the first InO cycle; of note, one patient with extensive extramedullary involvement before InO treatment experienced a remarkable tumor regression on PET/CT imaging. They all completed 2 cycles of InO. Two patients experienced relapse 8 and 9.5 months after InO initiation (one central nervous system relapse, the other breast relapse). Treatment-related adverse events (AEs) were primarily hematologic and manageable. Crucially, no sinusoidal obstruction syndrome (SOS) developed in any of the patients during the whole course of InO therapy and beyond.
conclusionInO appears to be a promising and well-tolerated salvage regimen for inducing remission in heavily pretreated B-ALL patients who have relapsed after both CAR-T therapy and allo-HSCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.